Paclitaxel

# Paclitaxel ## Overview - **Classification**: Taxane, Antineoplastic agent, Microtubule inhibitor - **Mechanism**: Promotes microtubule assembly and stabilizes them, preventing depolymerization. This disrupts mitotic spindle function, inhibiting cell division and leading to apoptosis. ## Primary Indications 1. **Ovarian Cancer** - First-line and subsequent therapy for advanced disease. 2. **Breast Cancer** - Adjuvant therapy, node-positive disease, and metastatic disease. 3. **Non-Small Cell Lung Cancer (NSCLC)** - First-line treatment in combination with cisplatin. 4. **AIDS-related Kaposi's Sarcoma** - Second-line therapy for advanced disease. ## Adult Dosing ### Standard Dosing **Ovarian Cancer (Combination Therapy)** - **Dose**: **175 mg/m²** - **Frequency**: Every 3 weeks - **Route**: IV infusion over 3 hours - **Special Considerations**: Often followed by carboplatin. **Breast Cancer (Adjuvant)** - **Dose**: **175 mg/m²** - **Frequency**: Every 3 weeks for 4 courses - **Route**: IV infusion over 3 hours (after doxorubicin/cyclophosphamide) **Breast Cancer (Weekly Regimen)** - **Dose**: **80 mg/m²** - **Frequency**: Weekly for 12 consecutive weeks - **Route**: IV infusion over 1 hour - **Special Considerations**: Can be used after doxorubicin/cyclophosphamide. **AIDS-related Kaposi's Sarcoma** - **Dose**: **135 mg/m²** - **Frequency**: Every 3 weeks - **Route**: IV infusion over 3 hours - **Special Considerations**: Lower neutrophil count threshold (750 cells/mm³) than other indications. ### Dose Adjustments - **Renal Impairment**: No specific dose adjustments for mild-to-moderate impairment. Use with caution in severe impairment (CrCl < 15 mL/min). - **Hepatic Impairment**: - **AST 1.5-10x ULN AND Bili 1.5-5x ULN**: Reduce dose by **50%**. - **AST >10x ULN OR Bili >5x ULN**: Reduce dose by **75%**. - **Severe impairment**: Consider avoiding or significant dose reduction. - **Elderly Patients**: No specific dose adjustment based on age alone. Monitor closely for myelosuppression and neuropathy. ## Pediatric Dosing *Note: Paclitaxel use in pediatric oncology is often off-label, BSA-based, and highly protocol-dependent.* ### Neonates (0-28 days) - **Dose**: Limited data, generally not recommended. - **Frequency**: N/A - **Maximum**: N/A - **Special Notes**: Use only in specific research protocols due to high toxicity and lack of safety data. ### Infants (1-12 months) - **Dose**: Typically **BSA-based (mg/m²)** for specific solid tumors (e.g., neuroblastoma, Kaposi's sarcoma). Example: **135-175 mg/m²**. - **Frequency**: Every 3 weeks (protocol dependent). - **Maximum**: Refer to specific oncology protocols. - **Special Notes**: Close monitoring for hypersensitivity and myelosuppression is crucial. Requires extensive premedication. ### Children (1-12 years) - **Dose**: Typically **BSA-based (mg/m²)**, as per specific oncology protocols. Common range: **135-175 mg/m²**. - **Frequency**: Every 3 weeks, or weekly for certain regimens. - **Maximum**: As per specific oncology protocol; generally adult mg/m² limits apply. - **Special Notes**: Essential to follow established oncology protocols. Ensure adequate premedication for hypersensitivity. ### Adolescents (13-18 years) - **Dose**: Generally follows adult **BSA-based (mg/m²)** dosing regimens for similar indications. Example: **175 mg/m²** or **80 mg/m²**. - **Frequency**: Every 3 weeks or weekly, depending on regimen. - **Maximum**: Adult maximum doses apply, based on BSA. - **Special Notes**: Body surface area calculation is critical. Monitor for adult-like toxicities. ## Safety Information ### Contraindications - **Absolute**: Known history of severe hypersensitivity reactions to paclitaxel or Cremophor EL (polyoxyl 35 castor oil). - **Absolute**: Baseline neutrophil count < **1,500 cells/mm³** (or < **1,000 cells/mm³** for AIDS-related Kaposi's sarcoma). - **Absolute**: Pregnancy and breastfeeding. ### Common Adverse Effects - **Very Common (>10%)**: Myelosuppression (neutropenia, leukopenia), peripheral neuropathy, alopecia, arthralgia/myalgia, hypersensitivity reactions (mild to moderate), nausea/vomiting, diarrhea. - **Common (1-10%)**: Mucositis, fatigue, edema, injection site reactions, bradycardia, hypotension. - **Serious but Rare**: Severe hypersensitivity (anaphylaxis), cardiac conduction abnormalities (e.g., AV block), severe neuropathic pain, interstitial pneumonia, acute myeloid leukemia (secondary). ### Key Drug Interactions - **CYP2C8/CYP3A4 Inhibitors (e.g., ketoconazole, erythromycin)**: May increase paclitaxel levels, increasing toxicity. Monitor closely; consider dose reduction. - **CYP2C8/CYP3A4 Inducers (e.g., rifampin, carbamazepine)**: May decrease paclitaxel levels, reducing efficacy. - **Cisplatin**: Administer **paclitaxel before cisplatin** to reduce myelosuppression. - **Doxorubicin**: Administer **paclitaxel after doxorubicin** to avoid increased doxorubicin levels. ## Monitoring & Follow-up - **Before Treatment**: Complete blood count (CBC) with differential, liver function tests (LFTs), renal function (CrCl), baseline ECG. - **During Treatment**: CBC with differential (prior to each cycle and at nadir), LFTs (periodically), neurological examination for neuropathy. - **Clinical Signs**: Watch for signs of hypersensitivity (dyspnea, hypotension, rash), infection (fever, chills), bleeding/bruising, or new/worsening neuropathic symptoms (pain, tingling, numbness). ## Clinical Pearls - 💡 **Tip 1**: Always premedicate with corticosteroids, H1-antagonists (e.g., diphenhydramine), and H2-antagonists (e.g., famotidine) to prevent severe hypersensitivity reactions. - 💡 **Tip 2**: Administer IV infusions using a 0.22-micron in-line filter and non-PVC (polyvinyl chloride) administration sets to prevent plasticizer leaching. - 💡 **Tip 3**: Peripheral neuropathy is a common and often dose-limiting toxicity; monitor closely and consider dose reduction or interruption for severe symptoms. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.